ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28th at 8:30 ...

Iterum Therapeutics (ITRM) plc announced that the U.S. Food and Drug Administration has approved Iterum’s new drug application for ...

Highlights,Iterum Therapeutics receives FDA approval for its new drug, ORLYNVAH.,ORLYNVAH targets uncomplicated urinary tract ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum ...

The clinical-stage pharmaceutical company said Friday that the Food and Drug Administration has approved its new drug application for Orlynvah as a treatment for uncomplicated urinary tract infections ...

Iterum Therapeutics (NASDAQ:ITRM) stock shot up 54% Friday after the company received FDA approval for its drug Orlynvah for ...

The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat a type of urinary tract ...

都柏林和芝加哥 - Iterum Therapeutics plc (NASDAQ:ITRM) 今天宣布,美国食品和药物管理局(FDA)已批准其新药申请ORLYNVAH™(sulopenem etzadroxil和probenecid)。该药物适用于治疗成年女性的非复杂性尿路感染(uUTIs),特别是由大肠杆菌、肺炎克雷伯菌或奇异变形杆菌引起的感染。ORLYNVAH™是美国首个获批的口服青霉烯类抗 ...

Corey Fishman, CEO of Iterum, expressed pride in achieving this FDA approval, emphasizing the drug’s potential to offer new hope for patients dealing with difficult-to-treat infections. The ...

Access our live advanced streaming chart for Iterum Therapeutics PLC stock, free of charge. This unique "area" or candle chart enables you to clearly notice the movements of this Iterum Therapeutics ...